Professor of Medicine
The Ohio State University
Columbus, Ohio, United States
Dr. Abraham earned his MD from Harvard Medical School and completed Internal Medicine residency and fellowships in Cardiovascular Disease and Advanced Heart Failure/Transplant Cardiology at the University of Colorado. He is a Professor of Internal Medicine, Physiology, and Cell Biology and College of Medicine Distinguished Professor at The Ohio State University. He has been recognized as one of the “Best Doctors in America” for 22 consecutive years. His research focuses on new drug and device devleopment for heart failure (HF). His work has led to the approval and adoption of several new therapies for HF, including beta-blockers, natriuretic peptides, cardiac resynchronization therapy, ultrafiltration, implantable hemodynamic monitoring, transvenous phrenic nerve stimulation, cardiac contractility modulation, transcatheter mitral valve repair, and baroreflex activation therapy.
Disclosure(s): Abbott: Consulting Fees (e.g., advisory boards) (Ongoing); AquaPass: Consulting Fees (e.g., advisory boards) (Ongoing); Bioventrix: Consulting Fees (e.g., advisory boards) (Ongoing); Cardiac Dimensions: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-privately held company (Ongoing); Cordio Medical: Consulting Fees (e.g., advisory boards) (Ongoing); CVRx: Consulting Fees (e.g., advisory boards) (Ongoing); Impulse Dynamics: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Innoventric: Consulting Fees (e.g., advisory boards) (Ongoing); JNJ V-Wave: Consulting Fees (e.g., advisory boards) (Ongoing); SCPharmaceuticals: Consulting Fees (e.g., advisory boards) (Terminated, October 31, 2025), Stock-publicly held company (excluding mutual/index funds) (Terminated, October 31, 2025); Sensible Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Vectorious Medtech: Consulting Fees (e.g., advisory boards) (Ongoing); WhiteSwell: Consulting Fees (e.g., advisory boards) (Ongoing); Zoll Respicardia: Consulting Fees (e.g., advisory boards) (Ongoing)
Optimizing Guideline Directed Medical Therapies for the Treatment of Heart Failure
Saturday, March 7, 2026
9:51 AM - 9:59 AM EST
Panel Discussion | Update of Heart Failure Management
Saturday, March 7, 2026
10:15 AM - 10:35 AM EST
Sunday, March 8, 2026
9:46 AM - 11:34 AM EST
Revisiting the Role of Cardiac Resynchronization Therapy for the Treatment of Heart Failure
Sunday, March 8, 2026
10:58 AM - 11:06 AM EST
Panel Discussion | Devices in Heart Failure
Sunday, March 8, 2026
11:14 AM - 11:34 AM EST
Monday, March 9, 2026
11:40 AM - 11:50 AM EST